Lenalidomide-rituximab therapy is effective in grade 1-2 follicular and mantle cell lymphoma, but its efficacy in diffuse large B-cell lymphoma (DLBCL), transformed large cell lymphoma (TL) and grade 3 follicular lymphoma (FLG3) is unknown. In this phase II trial, 45 patients with relapsed or refractory DLBCL (n ¼ 32), TL (n ¼ 9) or FLG3 (n ¼ 4) who had received 1-4 prior lines of treatment were given 20 mg oral lenalidomide on days 1-21 of each 28-day cycle, and intravenous rituximab (375 mg/m 2 ) weekly during cycle 1. Grade 3/4 hematological toxicities included neutropenia (53%), lymphopenia (40%), thrombocytopenia (33%), leukopenia (27%) and anemia (18%), with a median follow-up time of 29.1 months (range 14.7-52.0 months). Overall response (OR) rate was 33%; median response duration was 10.2 months. Median progression-free survival (PFS) and overall survival (OS) were 3.7 and 10.7 months, respectively. Nine of the 15 responding patients (three partial response (PR), six complete response (CR)) proceeded with stem cell transplantation (SCT) and were censored at the time of transplantation. When data were analyzed without censoring, median PFS remained 3.7 months and response duration increased to 30.9 months. Rituximab plus oral lenalidomide is well tolerated and effective for patients with relapsed/refractory DLBCL and TL. SCT after lenalidomide-rituximab is associated with prolonged response duration.
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin's lymphoma (NHL), has an aggressive natural history. 1 Follicular lymphoma (FL), an indolent NHL, is classified into three grades by World Health Organization criteria. 2 Grade 3 follicular lymphoma (FLG3) behaves clinically like DLBCL, with an aggressive natural history and clinical course. 3, 4 Transformed large cell lymphoma (TL) arises from an indolent FL that undergoes transformation to a more aggressive variant, DLBCL.
In the treatment of aggressive NHL, rational combinations of effective drugs have been shown to be active and often lead to better clinical outcomes than single-agent therapy. Rituximab, an anti-CD20 monoclonal antibody, is used in CD20 þ B-cell NHL in combination with standard chemotherapy. When added to standard frontline therapies (for example, HyperCVAD or CHOP), rituximab prolongs overall survival (OS) and progression-free survival (PFS). [5] [6] [7] Lenalidomide, a known immunomodulatory agent, has demonstrated single-agent activity for relapsed/ refractory aggressive B-cell NHLs, with response rates of 19-28% in DLBCL, 42-60% in FLG3 and 33-45% in TL. [8] [9] [10] Lenalidomide may act through several mechanisms in the tumor microenvironment. Preclinical studies have shown that lenalidomide repairs dysfunctional immune synapse formation and increases effector cell recognition of lymphoma. 11 Our group and others have also shown that rituximab and lenalidomide have synergistic antitumor effects in models of NHL. [12] [13] [14] [15] Owing to the observed single-agent activity of rituximab and lenalidomide, the potential to increase antibody-dependent cell-mediated cytotoxicity and the lack of overlapping toxicity profiles, we hypothesized that the combination may prove to be an effective therapeutic regimen for patients with relapsed/refractory NHL.
To test this hypothesis, we conducted a phase I/II doseescalation study of the combination in mantle cell lymphoma (MCL). 16 We identified the MTD to be 20 mg given daily for 21 days of every 28-day cycle with MCL patients. In the phase II study, patients with MCL or DLBCL, FLG3 or TL were treated at the MTD. In the MCL arm, the overall response (OR) rate was 57%, with a median overall survival (OS) of 23.4 months and median PFS of 11.1 months. 16 Other investigators have studied this novel combination and demonstrated efficacy in elderly patients with relapsed/refractory DLBCL 17 and patients with FL. 18, 19 However, there are still no data available regarding the activity of this combination in TL or FLG3. Here, we report the second arm of our phase II trial that enrolled patients with relapsed/refractory DLBCL, FLG3 and TL.
MATERIALS AND METHODS Patients
Patients with relapsed or refractory DLBCL, TL or FLG3 (follicular cleaved large cell lymphoma or follicular non-cleaved large cell lymphoma) treated at The University of Texas MD Anderson Cancer Center (Houston, TX, USA) were eligible for this study. The study was approved by the Institutional Review Board at MD Anderson Cancer Center, and was compliant with institutional guidelines and the Declaration of Helsinki. Informed written consent was obtained from all participants before enrollment. Additional inclusion criteria include the following: patients with bidimensional measurable disease; Eastern Cooperative Oncology Group performance status of p2; 1-4 prior lines of therapy; a serum bilirubin concentration o1.5 mg/dl and a serum creatinine concentration o2.0 mg/dl; platelet counts 475 000/mm 3 and an absolute neutrophil count 41000/mm 3 ; and aspartate amino transferase and alanine amino transferase concentrations of less than two times the upper limit of normal or more than five times the upper limit of normal, if hepatic metastases were present. Previous treatment with rituximab or bortezomib was permitted, regardless of sensitivity. This trial was registered at http://www.clinicaltrials.gov/ct/show/ NCT00294632.
Study design
All patients received 20 mg oral lenalidomide daily on days 1-21 of each 28-day cycle and 375 mg/m 2 of intravenous rituximab once a week for 4 weeks only during cycle 1. Anticoagulants, antithrombotic medication and prophylaxis for tumor lysis syndrome with allopurinol were not required by the protocol. Patients were treated until disease progression, stem cell transplantation (SCT) or withdrawal for toxicity.
The study design required a reduction of the lenalidomide dose from 20 to 15, 10, and 5 mg in a de-escalating fashion if there were grade 3 or 4 non-hematological toxicities or grade 4 hematological toxicities. Adverse events were assessed weekly during the first month of treatment and twice a month thereafter based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.
The primary efficacy end point was the OR rate (complete response (CR) or partial response (PR)). Response to treatment was assessed according to guidelines developed by an international workshop on lymphoma response criteria, 20 with restaging after every two cycles by CT scan and bone marrow biopsies. As our study was designed in 2004, we did not use the updated response criteria that require positron emission tomography (PET) or PET/CT in the response evaluation. 21 Both a regular radiological assessment and subsequent reassessment by the designated radiologist (NW-B) were done. The secondary efficacy end point was survival (OS).
Cell-of-origin classification
Immunohistochemical staining was performed on tissue samples from the 45 patients enrolled in the study. The hematoxylin-eosin-stained slides from each patient were reviewed for diagnosis. Three cases were unclassifiable, including one case of primary mediastinal large cell lymphoma, and these three cases were not included in the cell-of-origin statistical comparison. Immunohistochemical analysis was performed on 4-mm sections using a streptavidin-biotin complex technique, and antibodies reactive against the following antigens were utilized: CD3, CD10, CD20, BCL2, BCL6, FOXP1 and MUM1. The Visco-Young algorithm was used to classify the 42 cases as germinal center B-cell (GCB) or non-GCB DLBCL. 22 This method shows a high concordance with gene expression profiling analysis. Fluorescent in situ hybridization for BCL2 translocation was performed on 37 cases. Of those, 16 cases were positive for the translocation, which was consistent with the Visco-Young immunohistochemical algorithm classification.
Statistical analysis
The efficacy of the lenalidomide-rituximab regimen was monitored using Simon's 23 optimal two-stage design. This study design minimizes the expected sample size among competing designs. All patients enrolled on this study had received prior rituximab-containing regimens. As there are no published data on OR rates in patients with DLBCL retreated with rituximab, we estimated the response rate to be 25% on the basis of the experience of the faculty in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center. A 20% increase in the OR rate to 45% with the addition of lenalidomide would justify the assessment of this regimen in larger, more definitive trials. For the sample size calculation, we used a one-sided type 1 error rate of 5% and needed at least 80% power to conclude that the regimen elicits an OR rate significantly 425% if the true response rate of the regimen is 45% or higher. Based on these assumptions, if five or fewer responses (PR or better) were reported in the first 17 patients, we would conclude that the regimen is insufficiently effective to warrant further study. Otherwise, accrual would continue to a total of 41 patients. If 15 or more responses (PR or better) were noted in 41 patients, we would conclude that this regimen is sufficiently effective to warrant further study in a larger more definitive trial.
We used the Kaplan-Meier method to estimate PFS, OS and response duration. Analyses were done by intention to treat. To evaluate the association between response and disease diagnosis, we used Fisher's exact test. Response duration was calculated from the response date to the date of relapse, disease progression or death. As defined in the protocol, eligible patients who achieved PR or better and who requested subsequent consolidation with SCT were censored for all response assessments at the time of SCT. However, because of the unexpected response of the patients who went on to SCT, we also repeated the response assessments without censoring at the time of SCT. For the response duration calculation, responders who went off-study for any reason other than disease progression or death were censored on the CT date, either before going off-study or within 2 weeks of being off-study. Responders who did not experience disease progression but died of another reason were censored at the date of death. Responders who were still actively on study were censored at the survival date (that is, date of last follow-up) or the last CT date, whichever was later. We calculated the median time to event in months and corresponding 95% confidence interval (CI). OS was defined as the time from study entry until death due to any cause, or until the last survival date if still alive. 7 PFS was defined as the time from the start of treatment until lymphoma progression or death regardless of cause. 7 For the PFS calculation, patients who underwent SCT were censored on the last CT scan date, either before going off-study or within 2 weeks of being off-study. Patients who were still actively on study were censored at the survival date or the last CT date, whichever was later. All statistical calculations were done with SAS (version 9.1.3; SAS, Cary, NC, USA) or S-Plus 8.0 (TIBCO Software, Palo Alto, CA, USA).
RESULTS

From March 20 2008
to February 09 2011, 45 patients with a confirmed diagnosis of DLBCL (n ¼ 32), TL (n ¼ 9) or FLG3 (n ¼ 4) were enrolled. The median age was 66 years (range 24-84 years) and 62% were men. The median time from diagnosis to initiation of study treatment was 21 months (range 4-99 months). The median number of prior therapies was three (range 1-4). All patients had received prior rituximab-containing therapies. Table 1 lists all prior regimens. Seventeen patients presented with tumor masses (X 5 cm). Nine patients had received SCT as prior treatment before study entry.
For 20 of the 45 patients with assessment of the Ki-67 index at study entry, the median value was 70% (range 30-100%). Although we aimed to measure Ki-67 expression for all patients, we were not able to obtain specimens for all cases or in some cases there was not enough tissue for diagnostic or prognostic analyses.
Patients received a total of 185 cycles of study treatment, and the median lenalidomide dose was 20 mg (range 5-20 mg). The most common grades 1-2 hematological adverse events (X 10 events) were anemia, neutropenia, thrombocytopenia, leukopenia and lymphopenia (Table 2 ). Common grades 3-4 hematological adverse events (X 10 events) included neutropenia, thrombocytopenia, lymphopenia and leukopenia. The most common grades 1-2 non-hematological events (experienced by 440% of patients) were fatigue, nausea, neuropathy, dizziness, myalgia, diarrhea, elevated lactate dehydrogenase, hyperglycemia and hypoalbuminemia. Grades 3-4 non-hematological events were uncommon. The most common of these were elevated lactate dehydrogenase (four patients) and hypophosphatemia (four patients). Adverse events led to at least one dose reduction or interruption or discontinuation of treatment in 22 (55%) patients. Twelve (26%) patients required dose reductions for a total of 22 dose reductions during the study (Supplementary Table 1 ). The median number of cycles before the first dose reduction was 3 (range 2-29). Neutropenia was the most frequent cause of dose reduction (16 dose reductions), followed by rash (three dose reductions). Thrombocytopenia coexisted with neutropenia in three cases. Four patients needed a treatment break of at least 1 week. Five patients discontinued treatment due to the following toxicities: deep venous thrombosis with pulmonary embolism, myelodysplastic syndrome, hypercalcemia, pancytopenia and rash (one patient each). The patient with myelodysplastic syndrome was diagnosed during the first cycle after the findings of a bone marrow biopsy performed before the patient enrolled on study became available. Therefore, the myelodysplastic syndrome was not related to the study drugs. One patient died while on the study. The patient was admitted to an outside hospital for symptom control; shortly after admission, the patient died of natural causes. A post-mortem medical examination was declined; however, the patient had discontinued lenalidomide on day 18 of cycle one, 12 days before the date of death.
Forty-one of the 45 patients (41/45) were evaluated for response to treatment. Four patients were not evaluable because they discontinued treatment before completing one cycle. Ten (22.2%) patients achieved complete remission (CR) and five (11.1%) a PR; 11 (24.4%) had stable disease and 15 (33.3%) had progressive disease (Table 3 ). The median response duration for the 15 patients with an OR (PR and CR) was 10.2 months (95% CI 10.2 months to not reached (NR)) (Figure 1ai ). The median PFS was 3.7 months 
Abbreviations: BEAM, carmustine, etoposide, cytarabine; CMC-544, inotuzumab; Melphalan; CCI-779, temsirolimus; ESHAP, etoposide, methylprednisolone, cytarabine, cisplatin; GVD, gemcitabine, vinorelbine, pegylated liposomal doxorubicin; HDAC inhibitor, histone deacetylase inhibitor; PROTON, proton therapy; R-CHOP, rituximab plus cyclophosphamide, hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and prednisone; R-CNOP, rituximab, cyclophosphamide, mitoxantrone, vincristine, prednisone; R-CVP, rituximab, cyclophosphamide, vincristine, prednisolone; R-EPOCH, rituximab, etoposide, vincristine, doxorubicin, cyclophosphamide, prednisone; R-GEMOX, rituximab, gemcitabine, oxaliplatin; R-GIFOX, rituximab, gemcitabine, oxaliplatin, ifosfamide; R-HCVAD/R-MTX þ Ara-C, rituximab-hyper-cyclophosphamide, vincristine, adriamycin, dexamethasone alternating with rituximab, methotrexate and cytarabine; R-MINE, rituximab,mesna, ifosfamide, methotrexate, etoposide; RICE, rituximab þ ifosfamide þ carboplatin þ etoposide; SCT, stem cell transplantation; SGN-40, anti-huCD40 mAb; VEGF inhibitor; anti vascular endothelial growth factor receptor inhibitor; VP-16, etoposide; XRT, radiation therapy. Response Duration for OR/PR Patients N=15 (95% CI 1.8-5.8 months) (Figure 1bi) , and the median OS was 10.7 months (95% CI 6.6 months-NR) (Figure 1c) . The median follow-up time was 29.1 months (range 14.7-52.0 months).
Nine of the 15 patients who achieved a response (three PR, six CR) proceeded with SCT. As written in the protocol, for the response assessment, the SCT patients were censored at the time of transplantation. As such a large percentage of patients who responded to treatment went on to SCT (60%), we believe that the median response duration could have been longer. In fact, eight of the nine patients who had SCT were still alive as of 25 October 2012. Therefore, we also performed the response assessments without censoring at the SCT date. When the data were analyzed without censoring, the median PFS was 3.7 months (95% CI 1.8-5.9) and the median response duration was extended from 10.2 to 30.9 months (Figures 1aii and bii) .
Of 32 patients with DLBCL, nine (28%) had an OR (seven CRs and two PRs), with a median PFS of 2.8 months (95% CI 1.8-11. four patients with FLG3, one (25%) had a PR. Of the nine patients with TL, five (56%) had an OR (three CRs and two PRs), with median PFS of 4.3 months (95% CI 3.9 to NR) and median OS of 11.5 months (95% CI 6.3 to NR).
Fourteen of the 45 (31%) patients had tumor masses that were larger than 5 cm in the longest dimension. Of these patients, one achieved a CR, one achieved a PR, five had stable disease and seven developed progressive disease (Figure 2) . One of 45 patients is still being treated on protocol; one patient withdrew from study because of an inability to travel for study-related treatment and assessments; and 10 patients proceeded to SCT after achieving stable disease or better during the study (five DLBCL, one FLG3 and four TL). All 10 patients who went on to SCT achieved a CR.
Immunohistochemical staining of tissue sections and the ViscoYoung algorithm 20 were used to classify the cases as GCB or non-GCB DLBCL. When the clinical responses among the GCB and non-GCB DLBCL subtypes were compared, we found no significant difference (Supplementary Table 2 ; P 40.05).
DISCUSSION
In this phase II clinical trial, we assessed the clinical activity of oral lenalidomide and rituximab in relapsed/refractory DLBCL, FLG3 and TL. We found that the lenalidomide-rituximab combination is effective and well tolerated in patients with relapsed/refractory DLBCL, FLG3 and TL, with few toxicities. The adverse events experienced by patients were manageable and included mild to moderate bone marrow suppression. The safety profile is consistent with other published data on the lenalidomiderituximab combination. 16, 17 None of our patients discontinued treatment due to significant hematological toxicities. Most importantly, incidence of grade 3 or 4 febrile neutropenia was very low (7%) and was manageable. Furthermore, significant grade 3 or 4 non-hematological toxicities were a rare occurrence. Of the 185 total cycles of therapies delivered and with a median follow-up time of 29.1 months (range 14.7-52.0 months), there was no patient with myelodysplastic syndrome. This presents in contrast to conventional second-line chemotherapy for relapsed/ refractory DLBCL, which is associated with a significant hematological and non-hematological toxicity profile. 24 Moreover, this trial presented a unique occurrence: of the 45 evaluable patients, 15 achieved a PR or CR. However, nine (six CRs, three PRs) of these 15 responding patients chose to continue to SCT, at which point they were censored. As 60% of the responders (9/15) were not evaluable for further follow-up, our median response duration (10.2 months) and PFS (3.7 months) are likely underestimated. Additional study examining the response of stem cell transplant-eligible patients is warranted to more accurately determine response duration and PFS.
The OR rate for relapsed/refractory DLBCL patients in our study was 28%, which is comparable to the OR rate reported for singleagent lenalidomide (25 mg/day) in relapsed/refractory DLBCL. 10 However, the combination regimen resulted in significantly more CRs (22% vs 7%), with fewer grade 3 or 4 hematological toxicities using a lower lenalidomide dose (20 mg/day). In a recent study enrolling elderly patients with relapsed/refractory DLBCL (n ¼ 26), the lenalidomide-rituximab combination resulted in CR and OR rates of 35% after 8 months of maintenance lenalidomide, with an 18-month OS of 55.1%. 17 However, because of differences in treatment schedules, inclusion criteria and duration of study treatment, our results are not directly comparable to that study. We believe our findings add crucial information to the literature on DLBCL, a disease in which biological agents have not exhibited response rates seen in MCL, chronic lymphocytic leukemia, FL and multiple myeloma. The efficacy of lenalidomide-rituximab therapy could serve as a framework for further rational combination with other novel agents, such as carfilzomib (proteasome inhibitors), ibrutinib (BTK inhibitors) or chemotherapy to improve current DLBCL treatment.
DLBCL has been categorized into three distinct subtypes on the basis of gene expression profiling: activated B-cell-like, GCB-like and primary mediastinal B-cell lymphoma. [25] [26] [27] [28] [29] Recent findings support the idea that the cell-of-origin (that is, activated B-cell-like, GCB or primary mediastinal B-cell lymphoma) has high predictive value in patients treated with rituximab-based chemotherapy. 30, 31 Hernandez-Ilizaliturri et al. 32 recently showed that lenalidomide is more effective in non-GCB-like than GCB-like DLBCL in the relapsed/refractory setting. 32 However, in this study, we did not observe any variation in clinical responses to the lenalidomide-rituximab combination according to the cell of origin (Supplementary Table 2 ). Future prospective clinical trials, directly addressing this issue, will provide better insight into the differential antitumor activity of this novel combination in DLBCL subtypes.
Our study is the first to report on the activity of the lenalidomide-rituximab combination in patients with TL and FLG3. Taking into consideration the rare occurrence of FLG3, our single-center experience with four patients is inadequate to accurately determine the activity of this novel combination in FLG3. A future multicenter, international randomized trial enrolling a larger cohort of FLG3 patients is being planned to achieve sufficient statistical power for an accurate analysis of the lenalidomide-rituximab combination in these patients.
Management of TL has been a challenge. Even with high-dose chemotherapy (R-CHOP, if not treated previously) and autologous SCT, high relapse rates (50%) and treatment related mortality (18%) are seen. 33 Furthermore, the restrictive eligibility criteria for autologous SCT disqualify many patients. Compared with the options available for TL, the lenalidomide-rituximab combination resulted in high response rates, which were higher than those reported for single-agent lenalidomide in TL (OR rate: 56% vs 45%). 10 However, because TLs are also rare lymphomas, it is difficult to draw conclusions from our single-center experience. Larger multicenter, randomized trials will be necessary to confirm our results.
All patients enrolled in our study had been previously exposed to rituximab, and some had relapsed while on rituximab (Table 1) . Gisselbrecht et al. 24 reported that patients who relapsed within 1 year of initiating rituximab-based chemotherapy have poor prognoses and response rates. By contrast, lenalidomide may improve sensitivity to rituximab and enhance its antitumor effects, 14, 34 which is in agreement with our findings in this study. While the utility of extended dosing with rituximab has been well established for FL, [35] [36] [37] this approach in DLBCL (either post-induction or post-autologous SCT) has resulted in good responses but equivocal improvements in overall survival. [38] [39] [40] [41] By contrast, rituximab dosed with each cycle of therapy has been shown to prolong PFS in patients with relapsed/refractory DLBCL. 38 In our study, rituximab was given as four single, weekly doses of 375 mg/m 2 during the first cycle only. While this schedule is convenient for patients, it may have contributed to the moderate response rate in the DLBCL patients in our study. Recent studies in untreated and relapsed indolent lymphoma using a similar dose and schedule of lenalidomide as utilized in our study, but with rituximab given monthly have resulted in high OR rates with durable remissions. 19, 42, 43 In addition, several patients in these studies exhibited improved response with increased exposure to the combination. We recommend that future studies include rituximab for each cycle. Furthermore, given the nontoxic profile with lenalidomide and rituximab, future studies will likely prove that this combination may be useful in maintenance, especially in follicular and transformed lymphoma.
Although the lenalidomide and rituximab combination has shown significant synergistic activity in lymphoma cell lines and animal models, and in clinical trials with patients who had MCL, chronic lymphocytic leukemia and FL (grade 1 and 2), ours is only the second clinical trial to test this potential combination in DLBCL, FLG3 or TL. As these lymphomas are aggressive and patients often have relapsed or refractory disease, aggressive chemotherapy is often indicated. However, traditional regimens are often not tolerated in many patients due to their advanced age and associated comorbidities. We consider the lenalidomiderituximab combination to be a safe and effective alternative for these high-risk patients. Although the response rates appear similar to single-agent lenalidomide studies in this population, comparison between studies is complicated due to small number of patients and the limited exposure to rituximab. We recommend the design of future international, multicenter clinical trials that enroll patients with relapsed/refractory FLG3 and TL to determine the efficacy of this novel combination in that population.
Based on our experience, we believe that novel agents are more effective when used in combination. We were pleasantly surprised at what we observed from 9 of the 15 patients who achieved CR on lenalidomide-rituximab with subsequent SCT. When we did not censor those patients in our analysis, the response duration increased from 10.2 to 30.9 months. A future study with more patients treated with lenalidomide-rituximab followed by SCT will be necessary to consolidate this observation.
In conclusion, our study shows that the lenalidomide-rituximab combination is effective in high-risk relapsed/refractory DLBCL, FLG3 and TL. Larger trials should be conducted to further determine the therapeutic efficacy and value of this combination as a maintenance strategy in FLG3 and TL. Lenalidomiderituximab should be combined with other novel agents or chemotherapy regimens to improve current treatment of DLBCL.
